Background Accumulating works show that lncRNAs play critical roles in the development of gastric cancer (GC). LncRNA HLA complex group 18 (HCG18) was implicated in the progression of bladder cancer and glioma, but its role in GC is unknown. Methods RT‐PCR was used to detect HCG18 and miR‐141‐3p expression in GC specimen. GC cell lines (AGS and MKN‐28) were exploited as cell model. The biological effect of HCG18 on cancer cells was probed by CCK‐8, colony formation, flow cytometry, Transwell and wound‐healing experiments in vitro, and subcutaneous xenotransplanted tumor model and tail vein injection model in vivo. Interaction between HCG18 and miR‐141‐3p was determined by bioinformatics analysis, RT‐PCR, and luciferase reporter experiments. Downstream gene expression of miR‐141‐3p, including Wiskott–Aldrich syndrome protein interacting protein family member 1 (WIPF1), Yes associated protein 1 (YAP), and tafazzin (TAZ) were detected using Western blot. Results HCG18 was markedly up‐regulated in GC specimens, while miR‐141‐3p was markedly down‐regulated. Down‐regulation of HCG18 inhibited viability, migration, and invasion of GC cells, while miR‐141‐3p transfection led to opposite effect. HCG18 could down‐regulate miR‐141‐3p through adsorbing it, and a negative association between HCG18 and miR‐141‐3p was found in GC specimens. HCG18 promoted WIPF1, YAP and TAZ expression, nonetheless, such influence was reversed by co‐transfecting with miR‐141‐3p. Conclusion HCG18 was aberrantly up‐regulated in GC tissues, and it indirectly regulated the activity of Hippo signaling through counteracting miR‐141‐3p expression.

Colorectal cancer is one of the leading causes of deaths in China. The initial stages of colorectal cancer can be treated by surgery, radiation, and chemotherapy. However, in the advanced stages, it warrants an application of multimodality treatment. With advances in the medical field, there are applications of new modality of treatment that could possibly provide the appropriate treatment for the advanced stage tumours. The first site of metastasis after colorectal cancer is the liver and the conventional treatment to cure the metastatic lesion involves the administration of chemotherapy. With further advancement, chemotherapy has been directly administered at the thorough transarterial chemoembolization (TACE) which is a vascular intervention. With further advancement, the nonvascular intervention, such as radiofrequency ablations (RFAs), has been administered to the patients. A large amount of data support the use of vascular intervention (TACE) with ablation for hepatic carcinoma; there is no sufficient literature to support the application of the modality in the metastatic liver lesion. In this prospective observational study, we have enrolled 80 patients with metastatic liver lesion from the adenocarcinoma of colon or rectum, treated the patients with a combination of the TACE and ablation therapy, and followed up the patients for a period of 3 years. A multivariate analysis of the various factors that influence the prognosis and outcome has been studied and it has been concluded that the combination therapy is medically beneficial for individuals with aggressive liver lesions, improving overall as well as progression-free life span.

No abstract

To probe effect of Survivin-ASODN nano gene-carrier on apoptotic cycle of rectal cancer cells and expression of COX-2, SW837 cells were separated into blank control (A) group, liposome transfection Survivin-ASODN (B) group, and PLA-CS nanogene transfection Survivin-ASODN (C) group. The transfection and cell apoptosis were observed under a microscope fluorescence inversion. Cell proliferation was tested by MTT method, and cell cycle was gauged by flow cytometry. Survivin and COX-2 protein expressions were detected by Western blotting. SW837 cells in group A had no fluorescent signals, while there were obvious fluorescent signals in groups B and C. Transfection rate of Survivin-ASODN in group C (52.14%) was evidently higher than group B (38.16%) which presented lower proliferation rate than group A (P <0.05) and higher proliferation rate than group C (P <0.05). From apoptosis results, the apoptosis of group B (21.59%) and group C (30.87%) was significantly increased (P <0.05) with obvious increase in group B (P <0.05). Results from apoptosis cycle showed that, the proportion of cells in groups B and C in G1 phase were more than group A (P <0.05). Protein detection results showed increased protein content of Survivin and COX-2 in group A after transfection (P <0.05). Moreover, the protein contents of Survivin and COX-2 in groups B and C were reduced compared to group A (P <0.05) after transfection with lower in group C (P <0.05). Nanocarriers can efficiently deliver Survivin-ASODN to rectal cancer cells, and effectively promote cancer cell apoptosis and reduce COX-2 expression, providing a reference method for clinical treatment of rectal cancer.